CUREVAC N.V. O.N.
Commented by Nico Popp on April 20th, 2021 | 06:50 CEST
CureVac, BioNTech, PsyBio: Yesterday's game changers - and tomorrow's?
Vaccines against the coronavirus are changing everything. People who sat anxiously at home just a few weeks ago now dare to socialize again after their injection. Even if contact restrictions still apply - the feeling of being alive is different after the vaccination. German vaccine manufacturers, in particular, have used innovative mRNA technology to create vaccines that are largely scandal-free - and offer good protection. In the slipstream, new, innovative companies are already preparing to bring the next game changers to market. For investors, this can be a rewarding environment.
Read
Commented by Stefan Feulner on April 15th, 2021 | 07:15 CEST
Alibaba, The Place Holdings, CureVac - Great opportunities lie here!
The German vaccination disaster is going into the next round. After the AstraZeneca vaccine's back and forth and the question of whether only younger people, older people or no one should be vaccinated with the vaccine, the American vaccine manufacturer Johnson & Johnson is now experiencing delivery stoppages. The return to "normality" once again seems to be a long way off. Another question to ask yourself. What will future life in the new normal look like in the hard-pressed inner cities?
Read
Commented by Stefan Feulner on March 24th, 2021 | 09:06 CET
CureVac, Scottie Resources, Newmont - Is the monetary system at its end?
There is a dangerous mix brewing in the international financial markets. With the passage of the new USD 1.9 trillion US stimulus package, whose money will be used primarily to boost consumption, inflation expectations rise. The Fed expects inflation to average 2.4% in 2021. Nevertheless, the Fed intends to continue its path of loose monetary policy, which was accelerated during the Corona Crisis, until at least 2023. In doing so, Fed Chairman Powell violates the basic principle of central banks to take preventive action against inflation. There is a threat of monetary devaluation of historic proportions.
Read
Commented by Stefan Feulner on March 12th, 2021 | 07:25 CET
CureVac, Pollux Properties, SAP - Go for the latecomers!
At the moment, a shift from technology stocks to value stocks is taking place on the global stock markets. Companies that outperformed after bottoming out in March 2020 are losing disproportionately in the current market phase. In contrast, many investors are currently betting on the supposed re-opening winners such as TUI and Lufthansa & Co. Here, several stocks have enormous catch-up potential and are lagging behind in their performance.
Read
Commented by Nico Popp on March 10th, 2021 | 09:27 CET
BioNTech, CureVac, Cardiol Therapeutics: Biotech rockets off the launchpad
We all know that health is the greatest good. But it is only the last year or so that we've become fully aware of the fact that everything changes during a pandemic. Work, family, leisure time - no area of life is not currently under the influence of Covid-19. But even if lockdown fatigue is slowly but surely setting in, investors should remain wide awake. In many sectors, the course is currently being set for the future - especially in the pharmaceutical and biotech industries. Reason enough to take a closer look at these three stocks.
Read
Commented by Stefan Feulner on February 16th, 2021 | 11:00 CET
CureVac, Desert Gold, TUI - These are the big winners!
Slowly one no longer hears the topic of the Corona Crisis. Every day there are new developments on the table. Will the lockdown be lifted, when will people be allowed to travel again, and when will retail and restaurants reopen their doors? In the first phase of the pandemic, you could identify the winners, for example, online retailers like Amazon. We should keep a close eye on which industry is benefiting or who is starting to make a comeback.
Read
Commented by Stefan Feulner on February 9th, 2021 | 08:00 CET
CureVac, Cardiol Therapeutics, Bayer - roaring profits!
The race for the best and most effective vaccine is in full swing. After BioNTech and its partner Pfizer, Moderna and AstraZeneca were approved in Europe, but there are always obstacles. Over the weekend, for example, South Africa announced that it is forgoing the AstraZeneca vaccine for the time being. The background to this is its supposedly lower efficacy with the B.1.351 virus mutation. Somewhat unnoticed, another vaccine manufacturer is moving into pole position through innovative collaborations.
Read
Commented by Carsten Mainitz on January 12th, 2021 | 10:28 CET
CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!
The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.
Read
Commented by Stefan Feulner on December 21st, 2020 | 07:50 CET
CureVac, EXMceuticals, Formycom - the undiscovered profiteers of the crisis!
The Corona pandemic continues to be the dominant topic of our time. Not a day goes by when new achievements in the fight against the pandemic come to public attention. The battle against Covid-19 is becoming a multi-billion-dollar business. In addition to the well-known profiteers, the vaccine manufacturers BioNTech and Pfizer, Moderna and AstraZeneca and many smaller companies are also profiting. Their potential is still largely unknown on the stock market and is far from being fully exploited.
Read
Commented by André Will-Laudien on December 10th, 2020 | 10:59 CET
AdTiger, Formycon, CureVac - Brilliant to the finish line!
It seems strange that a single company should be worth as much as all its colleagues in the industry put together. There is no such thing - there is! Yesterday, Tesla had a valuation of USD 625 billion at the start of the stock market - that's more than all other car manufacturers put together. Of course, Elon Musk's creature has not been a pure car manufacturer for a long time. Tesla is a high-tech Company, led by a visionary who brings a new great idea from his inner design studio to the light of day every few weeks. With his visions about essential facts of the human future, he is as creative as Karl Lagerfeld and as crazy as Jean-Paul Gaultier. But everyone is looking for the favor of their customers and genius is what we urgently need in a pandemic environment.
Read